Beyond cervical cancer: Human papillomaviruses infection-related neoplasms and their prevention
DOI:
https://doi.org/10.6016/ZdravVestn.3037Keywords:
human papillomaviruses, benign and malignant anogenital lesions, neoplasms of the head and neck, vaccinationAbstract
Human papillomaviruses (HPV) are a very heterogenic group of viruses, which are etiologically related to many benign and malignant neoplastic lesions of squamous epithelium. They are also involved in adenocarcinoma carcinogenesis. It is wrong to believe that cervical cancer represents the only neoplasm that HPV is connected to. Studies have confirmed the connection between HPV infection and anogenital warts, respiratory and laryngeal papillomatosis, head and neck carcinomas and, last but not least, vulvar and vaginal carcinoma, rectal carcinoma and penile cancer. HPV infection is known as the most common sexually transmitted disease in developed countries, nearly all sexually active people will get HPV at some time in their life. Late age of sexual debut, low number of sexual partners and protective behaviour can prevent from acquiring the HPV infection. At the moment, there is no specific antiviral treatment for the HPV. The best-known method that can prevent HPV infection is vaccination. Vaccination against most common genotypes is considered as the most successful preventive measure to prevent most of the severe precancerous changes, cervical cancer and other benign and malignant lesions caused by HPV infection.
Downloads
Download data is not yet available.
References
<p>1. Liao BJ. Viruses and Human Cancer. Yale J Biol Med. 2006;79(3-4):115-22.<br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/17940621">17940621</a></p>
<p>2. Poljak M. Pomen okužbe s humanimi virusi papiloma v etiopatogenezi epitelijskih novotvorb grla in požiralnika. Ljubljana: M. Poljak; 1995.</p>
<p>3. Gale N, Poljak M, Luzar B, Vizjak A, Volavšek M, Cardes A. Tumorji v povezavi z okužbo s Človeškimi virusi papilloma (HPV). In: XLII. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem. 1.-2. december 2011; Ljubljana, Slovenija. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2011.</p>
<p>4. Andersson S, Rylander E, Larsson B, Strand A, Silfversvärd C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer. 2001;37(2):P246-50.</p>
<p>5. Poljak M, Petrovec M. Medicinska virologija. Ljubljana: Medicinski razgledi; 2001. pp. 41-59.</p>
<p>6. Ema Europa. Povzetek glavnih značilnosti zdravila Gardasil. Amsterdam: European medicines agencies; 2019 [cited 2019 Apr 16]. Available from: <a href="https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf">https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf</a>.</p>
<p>7. Poljak M, Kocjan B, Seme K, Fujs Komloš K, Potočnik M, Luzar B, et al. Humani virusi papiloma (HPV). Onkologija. 2005;9(2):60-72.</p>
<p>8. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24:S3.<br />DOI: <a href="https://doi.org/10.1016/j.vaccine.2006.05.031">10.1016/j.vaccine.2006.05.031</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/16950018">16950018</a></p>
<p>9. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99.<br />DOI: <a href="https://doi.org/10.1086/657321">10.1086/657321</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21067372">21067372</a></p>
<p>10. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. Principles of virology, Molecular Biology, Pathogenesis, and Control of Animal Viruses. 2nd ed. Washington: American Society for Microbiology; 2004.</p>
<p>11. Takač I, Geršak KGinekologija in porodništvo. Maribor: Univerza v Mariboru; 2016. p. 134, 243.</p>
<p>12. Onkološki inšitut. Program in register Zora. Ljubljana: Onkološki inštitut; 2020 [cited 2020 Aug 26]. Available from: <a href="https://zora.onko-i.si/">https://zora.onko-i.si/</a>.</p>
<p>13. Ivanuš U, Jerman T, Fokter AR, Takac I, Prevodnik VK, Marcec M, et al. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Radiol Oncol. 2018;52(4):399-412.<br />DOI: <a href="https://doi.org/10.2478/raon-2018-0036">10.2478/raon-2018-0036</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30216191">30216191</a></p>
<p>14. Dovnik A, Repše Fokter A. P16/Ki-67 immunostaining in the triage of postmenopausal women with low-grade cytology results. J Low Genit Tract Dis. 2020;24(3):235-7.<br />DOI: <a href="https://doi.org/10.1097/LGT.0000000000000539">10.1097/LGT.0000000000000539</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32574476">32574476</a></p>
<p>15. Dovnik A, Repše-Fokter A. p16/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology. Diagn Cytopathol. 2020;48(1):96-7.<br />DOI: <a href="https://doi.org/10.1002/dc.24339">10.1002/dc.24339</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31714671">31714671</a></p>
<p>16. Šekoranja D, Repše Fokter A. Triaging atypical squamous cells - cannot exclude high-grade squamous intraepithelial lesion with p16/Ki67 dual stain. J Low Genit Tract Dis. 2017;21(2):108-11.<br />DOI: <a href="https://doi.org/10.1097/LGT.0000000000000297">10.1097/LGT.0000000000000297</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/28244884">28244884</a></p>
<p>17. Takač I, Uršič-Vrščaj M, Repše-Fokter A, Kodric T, Rakar S, Mozina A, et al. Clinicopathological characteristics of cervical cancer between 2003 and 2005, after the introduction of a national cancer screening program in Slovenia. Eur J Obstet Gynecol Reprod Biol. 2008;140(1):82-9.<br />DOI: <a href="https://doi.org/10.1016/j.ejogrb.2008.02.019">10.1016/j.ejogrb.2008.02.019</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/18400358">18400358</a></p>
<p>18. Ball SL, Winder DM, Vaughan K, Hanna N, Levy J, Sterling JC, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol. 2011;83(8):1345-50.<br />DOI: <a href="https://doi.org/10.1002/jmv.22111">10.1002/jmv.22111</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21678438">21678438</a></p>
<p>19. Meyer T, Arndt R, Christophers E, Beckmann ER, Schröder S, Gissmann L, et al. Association of rare human papillomavirus types with genital premalignant and malignant lesions. J Infect Dis. 1998;178(1):252-5.<br />DOI: <a href="https://doi.org/10.1086/517447">10.1086/517447</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/9652449">9652449</a></p>
<p>20. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol. 1999;37(10):3316-22.<br />DOI: <a href="https://doi.org/10.1128/JCM.37.10.3316-3322.1999">10.1128/JCM.37.10.3316-3322.1999</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/10488198">10488198</a></p>
<p>21. Nacionalni inštitut za javno zdravje. Spolno prenesene okužbe v Sloveniji. Letno poročilo 2017. Ljubljana: NIJZ; 2017 [cited 2019 Apr 18]. Available from: <a href="https://www.nijz.si/sites/www.nijz.si/files/uploaded/spo-koncna-_2017.pdf">https://www.nijz.si/sites/www.nijz.si/files/uploaded/spo-koncna-_2017.pdf</a>.</p>
<p>22. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15.<br />DOI: <a href="https://doi.org/10.1016/S1470-2045(12)70137-7">10.1016/S1470-2045(12)70137-7</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/22575588">22575588</a></p>
<p>23. Poljak M, Kocjan BJ, Oštrbenk A. Okužbe s HPV. In: Obnovitveni kolposkopski tečaj. Zbornik. 9. september 2016; Maribor, Ljubljana. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo: Slovensko zdravniško društvo in Onkološki inštitut Ljubljana Ljubljana; 2016. pp. 9-29.</p>
<p>24. Onkološki inštitut Ljubljana. Register raka Republike Slovenije. Slovenija in rak. Ljubljana: Onkološki inštitut; 2018 [cited 2019 Jun 05]. Available from: <a href="http://slora.si/analizaslo">http://slora.si/analizaslo</a>.</p>
<p>25. Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305-13.<br />DOI: <a href="https://doi.org/10.2147/IJWH.S68979">10.2147/IJWH.S68979</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/25848321">25848321</a></p>
<p>26. Sinno AK, Saraiya M, Thompson TD, Hernandez BY, Goodman MT, Steinau M, et al. Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer from a Registry-Based Population. Obstet Gynecol. 2014;123(4):817-21.<br />DOI: <a href="https://doi.org/10.1097/AOG.0000000000000171">10.1097/AOG.0000000000000171</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/24785610">24785610</a></p>
<p>27. Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer—implications for prevention and treatment. Transl Androl Urol. 2017;6(5):791-802.<br />DOI: <a href="https://doi.org/10.21037/tau.2017.06.27">10.21037/tau.2017.06.27</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29184775">29184775</a></p>
<p>28. Derkay C. Recurrent Respiratory Papillomatosis, Rare Diseases Database. Washington: National organization for rare disorders; 2019 [cited 2019 Apr 20]. Available from: <a href="https://rarediseases.org/rare-diseases/recurrent-respiratory-papillomatosis/">https://rarediseases.org/rare-diseases/recurrent-respiratory-papillomatosis/</a>.</p>
<p>29. Schiff BA. Oropharyngeal Squamous Cell Carcinoma. Kenilworth: Merck Sharp and Dohme Corp; 2019 [cited 2019 Apr 18]. Available from: <a href="https://msdmanuals.com/professional/ear,-nose,-and-throat-disorders/tumors-of-the-head-and-neck/oropharyngeal-squamous-cell-carcinoma">https://msdmanuals.com/professional/ear,-nose,-and-throat-disorders/tumors-of-the-head-and-neck/oropharyngeal-squamous-cell-carcinoma</a>.</p>
<p>30. Haddad RI. Human papillomavirus associated head and neck cancer. Massachusetts: UpToDate; 2019 [cited 2019 Apr 18]. Available from: <a href="https://uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer#H2128117224">https://uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer#H2128117224</a>.</p>
<p>31. Poljak M. Evropska agencija za zdavila (EMEA) odobrila še peto indikacijo za štirivalentno cepivo proti okužbi s HPV. ISIS. 2008;17(8):92-4.</p>
<p>32. Nationalni inštitut za javno zdravje. Najpogostejša vprašanja in odgovori o okužbi s HPV, raku materničnega vratu in cepljenju proti HPV. Ljubljana: NIJZ; 2019 [cited 2019 Aug 31]. Available from: <a href="http://nijz.si/sl/najpogostejsa-vprasanja-in-odgovori-o-okuzbi-s-hpv-raku-maternicnega-vratu-in-cepljenju-proti-hpv-1">http://nijz.si/sl/najpogostejsa-vprasanja-in-odgovori-o-okuzbi-s-hpv-raku-maternicnega-vratu-in-cepljenju-proti-hpv-1</a>.</p>
<p>33. European Medicines Agency. B. Silgard – Summary product characteristics. Amsterdam: EMA; 2019 [cited 2019 Jun 05]. Available from: <a href="https://ema.europa.eu/documents/product-information/silgard-epar-product-information_sl.pdf">https://ema.europa.eu/documents/product-information/silgard-epar-product-information_sl.pdf</a>.</p>
<p>34. European Medicines Agency. C. Gardasil 9 – Summary product characteristics. Amsterdam: EMA; 2019 [cited 2019 Jun 05]. Available from: <a href="https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf">https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf</a>.</p>
<p>35. Mikuš M, Nerat B, Takač Kašan K, Esih M, Vogrin V, Takač I. Cepljenje HPV in vprašanje zamujenih generacij. In: 28. posvetovanje Medicina, pravo and družba. Globalizacija medicine v 21. stoletju. Konferenčni zbornik. 28.–30. 3. 2019; Maribor, Slovenija. Maribor: Univerza v Mariboru, Pravna fakulteta; 2019.</p>
<p>36. Nacionalni inštiut za javno zdravje. Program cepljenja in zaščite z zdravili za leto 2018. Ljubljana: NIJZ; 2019 [cited 2019 Jun 05]. Available from: <a href="http://nijz.si/sites/nijz.si/files/uploaded/navodila_za_izvajanje_ip_2018.pdf">http://nijz.si/sites/nijz.si/files/uploaded/navodila_za_izvajanje_ip_2018.pdf</a>.</p>
<p>37. Nacionalni inštiut za javno zdravje. Poročilo o izvajanju cepljenja v Sloveniji v letu 2019 – preliminarni podatki. Ljubljana: NIJZ; 2019 [cited 2019 Sep 08]. Available from: <a href="https://www.nijz.si/sites/www.nijz.si/files/uploaded/preliminarno_porocilo_2019_ostala_cepljena.pdf">https://www.nijz.si/sites/www.nijz.si/files/uploaded/preliminarno_porocilo_2019_ostala_cepljena.pdf</a>.</p>
<p>38. Nacionalni inštiut za javno zdravje. Spremljanje precepljenosti (deleža cepljenih). Ljubljana: NIJZ; 2019 [cited 2019 Jun 05]. Available from: <a href="http://nijz.si/sl/spremljanje-precepljenosti-deleza-cepljenih">http://nijz.si/sl/spremljanje-precepljenosti-deleza-cepljenih</a>.</p>
<p>39. Thomas Cox J, Palefsky JM. Human papillomavirus vaccination. Massachusetts: UpToDate; 2019 [cited 2019 Jun 05]. Available from: <a href="https://uptodate.com/contents/human-papillomavirus-vaccination>https://uptodate.com/contents/human-papillomavirus-vaccination">https://uptodate.com/contents/human-papillomavirus-vaccination>https://uptodate.com/contents/human-papillomavirus-vaccination</a>.</p>
<p>40. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018;41(4):329-46.<br />DOI: <a href="https://doi.org/10.1007/s40264-017-0625-z">10.1007/s40264-017-0625-z</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29280070">29280070</a></p>
<p>41. Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine. 2006;24:S3.<br />DOI: <a href="https://doi.org/10.1016/j.vaccine.2006.06.064">10.1016/j.vaccine.2006.06.064</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/16950014">16950014</a></p>
<p>42. Chow EP, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. ;17(1):68-77.<br />DOI: <a href="https://doi.org/10.1016/S1473-3099(16)30116-5">10.1016/S1473-3099(16)30116-5</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/27282422">27282422</a></p>
<p>43. Sočan M. Epidemiološko spremljanje nalezljivih bolezni v Sloveniji v letu 2017. Ljubljana: Nacionalni inštitut za javno zdravje; 2019 [cited 2019 Jun 05]. Available from: <a href="http://nijz.si/sites/nijz.si/files/uploaded/epidemiolosko_spremljanje_nb_v_sloveniji_2017_november2018_1.pdf">http://nijz.si/sites/nijz.si/files/uploaded/epidemiolosko_spremljanje_nb_v_sloveniji_2017_november2018_1.pdf</a>.</p>
<p>44. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily MC, et al.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497-509.<br />DOI: <a href="https://doi.org/10.1016/S0140-6736(19)30298-3">10.1016/S0140-6736(19)30298-3</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31255301">31255301</a></p>
<p>2. Poljak M. Pomen okužbe s humanimi virusi papiloma v etiopatogenezi epitelijskih novotvorb grla in požiralnika. Ljubljana: M. Poljak; 1995.</p>
<p>3. Gale N, Poljak M, Luzar B, Vizjak A, Volavšek M, Cardes A. Tumorji v povezavi z okužbo s Človeškimi virusi papilloma (HPV). In: XLII. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem. 1.-2. december 2011; Ljubljana, Slovenija. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2011.</p>
<p>4. Andersson S, Rylander E, Larsson B, Strand A, Silfversvärd C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer. 2001;37(2):P246-50.</p>
<p>5. Poljak M, Petrovec M. Medicinska virologija. Ljubljana: Medicinski razgledi; 2001. pp. 41-59.</p>
<p>6. Ema Europa. Povzetek glavnih značilnosti zdravila Gardasil. Amsterdam: European medicines agencies; 2019 [cited 2019 Apr 16]. Available from: <a href="https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf">https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf</a>.</p>
<p>7. Poljak M, Kocjan B, Seme K, Fujs Komloš K, Potočnik M, Luzar B, et al. Humani virusi papiloma (HPV). Onkologija. 2005;9(2):60-72.</p>
<p>8. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24:S3.<br />DOI: <a href="https://doi.org/10.1016/j.vaccine.2006.05.031">10.1016/j.vaccine.2006.05.031</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/16950018">16950018</a></p>
<p>9. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99.<br />DOI: <a href="https://doi.org/10.1086/657321">10.1086/657321</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21067372">21067372</a></p>
<p>10. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. Principles of virology, Molecular Biology, Pathogenesis, and Control of Animal Viruses. 2nd ed. Washington: American Society for Microbiology; 2004.</p>
<p>11. Takač I, Geršak KGinekologija in porodništvo. Maribor: Univerza v Mariboru; 2016. p. 134, 243.</p>
<p>12. Onkološki inšitut. Program in register Zora. Ljubljana: Onkološki inštitut; 2020 [cited 2020 Aug 26]. Available from: <a href="https://zora.onko-i.si/">https://zora.onko-i.si/</a>.</p>
<p>13. Ivanuš U, Jerman T, Fokter AR, Takac I, Prevodnik VK, Marcec M, et al. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Radiol Oncol. 2018;52(4):399-412.<br />DOI: <a href="https://doi.org/10.2478/raon-2018-0036">10.2478/raon-2018-0036</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30216191">30216191</a></p>
<p>14. Dovnik A, Repše Fokter A. P16/Ki-67 immunostaining in the triage of postmenopausal women with low-grade cytology results. J Low Genit Tract Dis. 2020;24(3):235-7.<br />DOI: <a href="https://doi.org/10.1097/LGT.0000000000000539">10.1097/LGT.0000000000000539</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32574476">32574476</a></p>
<p>15. Dovnik A, Repše-Fokter A. p16/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology. Diagn Cytopathol. 2020;48(1):96-7.<br />DOI: <a href="https://doi.org/10.1002/dc.24339">10.1002/dc.24339</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31714671">31714671</a></p>
<p>16. Šekoranja D, Repše Fokter A. Triaging atypical squamous cells - cannot exclude high-grade squamous intraepithelial lesion with p16/Ki67 dual stain. J Low Genit Tract Dis. 2017;21(2):108-11.<br />DOI: <a href="https://doi.org/10.1097/LGT.0000000000000297">10.1097/LGT.0000000000000297</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/28244884">28244884</a></p>
<p>17. Takač I, Uršič-Vrščaj M, Repše-Fokter A, Kodric T, Rakar S, Mozina A, et al. Clinicopathological characteristics of cervical cancer between 2003 and 2005, after the introduction of a national cancer screening program in Slovenia. Eur J Obstet Gynecol Reprod Biol. 2008;140(1):82-9.<br />DOI: <a href="https://doi.org/10.1016/j.ejogrb.2008.02.019">10.1016/j.ejogrb.2008.02.019</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/18400358">18400358</a></p>
<p>18. Ball SL, Winder DM, Vaughan K, Hanna N, Levy J, Sterling JC, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol. 2011;83(8):1345-50.<br />DOI: <a href="https://doi.org/10.1002/jmv.22111">10.1002/jmv.22111</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21678438">21678438</a></p>
<p>19. Meyer T, Arndt R, Christophers E, Beckmann ER, Schröder S, Gissmann L, et al. Association of rare human papillomavirus types with genital premalignant and malignant lesions. J Infect Dis. 1998;178(1):252-5.<br />DOI: <a href="https://doi.org/10.1086/517447">10.1086/517447</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/9652449">9652449</a></p>
<p>20. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol. 1999;37(10):3316-22.<br />DOI: <a href="https://doi.org/10.1128/JCM.37.10.3316-3322.1999">10.1128/JCM.37.10.3316-3322.1999</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/10488198">10488198</a></p>
<p>21. Nacionalni inštitut za javno zdravje. Spolno prenesene okužbe v Sloveniji. Letno poročilo 2017. Ljubljana: NIJZ; 2017 [cited 2019 Apr 18]. Available from: <a href="https://www.nijz.si/sites/www.nijz.si/files/uploaded/spo-koncna-_2017.pdf">https://www.nijz.si/sites/www.nijz.si/files/uploaded/spo-koncna-_2017.pdf</a>.</p>
<p>22. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15.<br />DOI: <a href="https://doi.org/10.1016/S1470-2045(12)70137-7">10.1016/S1470-2045(12)70137-7</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/22575588">22575588</a></p>
<p>23. Poljak M, Kocjan BJ, Oštrbenk A. Okužbe s HPV. In: Obnovitveni kolposkopski tečaj. Zbornik. 9. september 2016; Maribor, Ljubljana. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo: Slovensko zdravniško društvo in Onkološki inštitut Ljubljana Ljubljana; 2016. pp. 9-29.</p>
<p>24. Onkološki inštitut Ljubljana. Register raka Republike Slovenije. Slovenija in rak. Ljubljana: Onkološki inštitut; 2018 [cited 2019 Jun 05]. Available from: <a href="http://slora.si/analizaslo">http://slora.si/analizaslo</a>.</p>
<p>25. Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305-13.<br />DOI: <a href="https://doi.org/10.2147/IJWH.S68979">10.2147/IJWH.S68979</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/25848321">25848321</a></p>
<p>26. Sinno AK, Saraiya M, Thompson TD, Hernandez BY, Goodman MT, Steinau M, et al. Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer from a Registry-Based Population. Obstet Gynecol. 2014;123(4):817-21.<br />DOI: <a href="https://doi.org/10.1097/AOG.0000000000000171">10.1097/AOG.0000000000000171</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/24785610">24785610</a></p>
<p>27. Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer—implications for prevention and treatment. Transl Androl Urol. 2017;6(5):791-802.<br />DOI: <a href="https://doi.org/10.21037/tau.2017.06.27">10.21037/tau.2017.06.27</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29184775">29184775</a></p>
<p>28. Derkay C. Recurrent Respiratory Papillomatosis, Rare Diseases Database. Washington: National organization for rare disorders; 2019 [cited 2019 Apr 20]. Available from: <a href="https://rarediseases.org/rare-diseases/recurrent-respiratory-papillomatosis/">https://rarediseases.org/rare-diseases/recurrent-respiratory-papillomatosis/</a>.</p>
<p>29. Schiff BA. Oropharyngeal Squamous Cell Carcinoma. Kenilworth: Merck Sharp and Dohme Corp; 2019 [cited 2019 Apr 18]. Available from: <a href="https://msdmanuals.com/professional/ear,-nose,-and-throat-disorders/tumors-of-the-head-and-neck/oropharyngeal-squamous-cell-carcinoma">https://msdmanuals.com/professional/ear,-nose,-and-throat-disorders/tumors-of-the-head-and-neck/oropharyngeal-squamous-cell-carcinoma</a>.</p>
<p>30. Haddad RI. Human papillomavirus associated head and neck cancer. Massachusetts: UpToDate; 2019 [cited 2019 Apr 18]. Available from: <a href="https://uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer#H2128117224">https://uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer#H2128117224</a>.</p>
<p>31. Poljak M. Evropska agencija za zdavila (EMEA) odobrila še peto indikacijo za štirivalentno cepivo proti okužbi s HPV. ISIS. 2008;17(8):92-4.</p>
<p>32. Nationalni inštitut za javno zdravje. Najpogostejša vprašanja in odgovori o okužbi s HPV, raku materničnega vratu in cepljenju proti HPV. Ljubljana: NIJZ; 2019 [cited 2019 Aug 31]. Available from: <a href="http://nijz.si/sl/najpogostejsa-vprasanja-in-odgovori-o-okuzbi-s-hpv-raku-maternicnega-vratu-in-cepljenju-proti-hpv-1">http://nijz.si/sl/najpogostejsa-vprasanja-in-odgovori-o-okuzbi-s-hpv-raku-maternicnega-vratu-in-cepljenju-proti-hpv-1</a>.</p>
<p>33. European Medicines Agency. B. Silgard – Summary product characteristics. Amsterdam: EMA; 2019 [cited 2019 Jun 05]. Available from: <a href="https://ema.europa.eu/documents/product-information/silgard-epar-product-information_sl.pdf">https://ema.europa.eu/documents/product-information/silgard-epar-product-information_sl.pdf</a>.</p>
<p>34. European Medicines Agency. C. Gardasil 9 – Summary product characteristics. Amsterdam: EMA; 2019 [cited 2019 Jun 05]. Available from: <a href="https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf">https://ema.europa.eu/documents/product-information/gardasil-9-epar-product-information_sl.pdf</a>.</p>
<p>35. Mikuš M, Nerat B, Takač Kašan K, Esih M, Vogrin V, Takač I. Cepljenje HPV in vprašanje zamujenih generacij. In: 28. posvetovanje Medicina, pravo and družba. Globalizacija medicine v 21. stoletju. Konferenčni zbornik. 28.–30. 3. 2019; Maribor, Slovenija. Maribor: Univerza v Mariboru, Pravna fakulteta; 2019.</p>
<p>36. Nacionalni inštiut za javno zdravje. Program cepljenja in zaščite z zdravili za leto 2018. Ljubljana: NIJZ; 2019 [cited 2019 Jun 05]. Available from: <a href="http://nijz.si/sites/nijz.si/files/uploaded/navodila_za_izvajanje_ip_2018.pdf">http://nijz.si/sites/nijz.si/files/uploaded/navodila_za_izvajanje_ip_2018.pdf</a>.</p>
<p>37. Nacionalni inštiut za javno zdravje. Poročilo o izvajanju cepljenja v Sloveniji v letu 2019 – preliminarni podatki. Ljubljana: NIJZ; 2019 [cited 2019 Sep 08]. Available from: <a href="https://www.nijz.si/sites/www.nijz.si/files/uploaded/preliminarno_porocilo_2019_ostala_cepljena.pdf">https://www.nijz.si/sites/www.nijz.si/files/uploaded/preliminarno_porocilo_2019_ostala_cepljena.pdf</a>.</p>
<p>38. Nacionalni inštiut za javno zdravje. Spremljanje precepljenosti (deleža cepljenih). Ljubljana: NIJZ; 2019 [cited 2019 Jun 05]. Available from: <a href="http://nijz.si/sl/spremljanje-precepljenosti-deleza-cepljenih">http://nijz.si/sl/spremljanje-precepljenosti-deleza-cepljenih</a>.</p>
<p>39. Thomas Cox J, Palefsky JM. Human papillomavirus vaccination. Massachusetts: UpToDate; 2019 [cited 2019 Jun 05]. Available from: <a href="https://uptodate.com/contents/human-papillomavirus-vaccination>https://uptodate.com/contents/human-papillomavirus-vaccination">https://uptodate.com/contents/human-papillomavirus-vaccination>https://uptodate.com/contents/human-papillomavirus-vaccination</a>.</p>
<p>40. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018;41(4):329-46.<br />DOI: <a href="https://doi.org/10.1007/s40264-017-0625-z">10.1007/s40264-017-0625-z</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29280070">29280070</a></p>
<p>41. Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine. 2006;24:S3.<br />DOI: <a href="https://doi.org/10.1016/j.vaccine.2006.06.064">10.1016/j.vaccine.2006.06.064</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/16950014">16950014</a></p>
<p>42. Chow EP, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. ;17(1):68-77.<br />DOI: <a href="https://doi.org/10.1016/S1473-3099(16)30116-5">10.1016/S1473-3099(16)30116-5</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/27282422">27282422</a></p>
<p>43. Sočan M. Epidemiološko spremljanje nalezljivih bolezni v Sloveniji v letu 2017. Ljubljana: Nacionalni inštitut za javno zdravje; 2019 [cited 2019 Jun 05]. Available from: <a href="http://nijz.si/sites/nijz.si/files/uploaded/epidemiolosko_spremljanje_nb_v_sloveniji_2017_november2018_1.pdf">http://nijz.si/sites/nijz.si/files/uploaded/epidemiolosko_spremljanje_nb_v_sloveniji_2017_november2018_1.pdf</a>.</p>
<p>44. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily MC, et al.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497-509.<br />DOI: <a href="https://doi.org/10.1016/S0140-6736(19)30298-3">10.1016/S0140-6736(19)30298-3</a><br />PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31255301">31255301</a></p>
Downloads
Published
2021-04-30
Issue
Section
Professional Article
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
How to Cite
1.
Beyond cervical cancer: Human papillomaviruses infection-related neoplasms and their prevention. ZdravVestn [Internet]. 2021 Apr. 30 [cited 2024 Nov. 2];90(3-4):208-1. Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/3037
